Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Operating Expenses (2021 - 2026)

MoonLake Immunotherapeutics' Operating Expenses history spans 6 years, with the latest figure at $70.0 million for Q1 2026.

  • Quarterly Operating Expenses rose 47.47% to $70.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $267.4 million through Mar 2026, up 56.58% year-over-year, with the annual reading at $244.8 million for FY2025, 71.1% up from the prior year.
  • Operating Expenses came in at $70.0 million for Q1 2026, up from $65.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $71.4 million in Q3 2025 to a low of $12.9 million in Q1 2023.
  • The 5-year median for Operating Expenses is $19.8 million (2024), against an average of $33.9 million.
  • The largest YoY upside for Operating Expenses was 16840.81% in 2022 against a maximum downside of 68.84% in 2022.
  • MoonLake Immunotherapeutics' Operating Expenses stood at $16.7 million in 2022, then fell by 9.99% to $15.0 million in 2023, then soared by 229.9% to $49.6 million in 2024, then surged by 31.54% to $65.2 million in 2025, then rose by 7.37% to $70.0 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Operating Expenses are $70.0 million (Q1 2026), $65.2 million (Q4 2025), and $71.4 million (Q3 2025).